Combined RAAS and NEP Inhibition
Keyword(s):
The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. Combined NEP and ACE blockade although unsuccessful with omapatrilat in the OVERTURE trial, found success with sacubitril/valsartan in the Paradigm-HF trial. The results of PARADIGM-HF trial represent one of the most significant breakthroughs in the management of HF of the last decade, representing a shift from neurohomonal antagonism to neurohormonal modulation.
2006 ◽
Vol 8
(5)
◽
pp. 356-364
◽
Keyword(s):
2008 ◽
Vol 102
(1)
◽
pp. 77-78
◽
2010 ◽
Vol 23
(6)
◽
pp. 687-690
◽
2016 ◽
Vol 139
(1)
◽
pp. 212-219
◽
2008 ◽
Vol 9
(2)
◽
pp. 124-127
◽
2013 ◽
Vol 9
(4)
◽
pp. 427-432